LEXEO Therapeutics
Peter Janki is a biochemistry graduate from Case Western Reserve University, holding a Bachelor of Science degree obtained in 2009. Peter Janki is currently the Manager of Nonclinical Bioanalytical Development at LEXEO Therapeutics since September 2023. Prior to this role, Peter Janki worked at Maze Therapeutics from July 2019 to September 2023, advancing from Scientist I to Scientist II, focusing on gene therapy. Peter Janki's earlier experience includes senior research positions at Calico Life Sciences and Stanford University, alongside a research assistant role at Rockefeller University. Additional contributions include undergraduate research at Case Western Reserve University and a summer internship at the US Senate.
This person is not in the org chart
LEXEO Therapeutics
LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine.